All entries for: Leap Therapeutics

Flagging what CEO Douglas Onsi called the “difficult market environment,” immune specialist Leap Therapeutics will lay off approximately half of its workforce. The biotech made the announcement alongside its first-quarter 2025 earnings report, where it posted a net loss of $15.4 million, falling further into the red compared to the same period in 2024, during which it was operating with a $13.8 million deficit. Leap pointed to heightened R&D expenses as the reason for the increase in its loss.